Company: REVB
Filing Date: 2025-10-30
Form Type: PRE 14A
Source: 0001193125-25-258785
Chunk: 12

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-10-30
Form: PRE 14A
Chunk 12
---
 Company would obtain the funding necessary to advance its clinical development programs and maintain its operations. The Board further noted that this approach entailed substantially lower transaction costs than a registered public offering, an underwritten financing, or the issuance of new convertible securities. By avoiding underwriting discounts, and extensive offering documentation, the Company would maximize the net proceeds available for use.

Timing was also a critical factor. The Company’s capital requirements demanded swift action, and a warrant inducement could be completed more rapidly than other financing methods. This provided immediate liquidity without the extended marketing, negotiations, or regulatory reviews that alternative transactions might require.

Although the warrant inducement will result in meaningful dilution to existing stockholders, the Board determined that it represents the most viable and cost-effective method for the Company to obtain the financing it needs under the circumstances.

Reasons for the Stockholder Approval

Under applicable Nasdaq rules and the terms of the Warrant Inducement, in no event may the Company issue to the holders shares of common stock equal to greater than 19.99% of the shares of common stock outstanding immediately prior to the Warrant Inducement, unless the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap in accordance with applicable Nasdaq rules. Accordingly, Proposal 1 is being submitted to the stockholders in order to comply with Rule 5635(d) of the Nasdaq Stock Market Rules.

<div align='center'>6</div>

Consequences of Not Approving this Proposal

After careful consideration, our Board of Directors believes that the issuance of the Class I Common Stock Warrants is in the best interest of the Company in order to give it the best chance of remaining on Nasdaq. If our stockholders do not approve this proposal, we are required to hold a stockholder meeting every sixty (60) days until such approval is obtained. In addition, if this Proposal 1 is not approved by our stockholders we are prohibited from issuing, entering into any agreement to issue or announcing the issuance or proposed issuance of any shares of our common stock or common stock equivalents until we receive such stockholder approval. The stockholder meetings was duly held on October 29, 2025, which each contained this exact Proposal, were adjourned due to an insufficient quorum present at each respective meeting, and as a result have caused the Company to incur approximately $50,000 in additional expenses in order to hold the Meeting and each subsequent stockholder meeting will result in a similar cost to approve the Proposal.